GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Other Current Payables

Chimeric Therapeutics (ASX:CHM) Other Current Payables : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Other Current Payables?

Chimeric Therapeutics's Other Current Payables for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Chimeric Therapeutics's quarterly Other Current Payables increased from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$3.41 Mil) but then declined from Jun. 2023 (A$3.41 Mil) to Dec. 2023 (A$0.00 Mil).

Chimeric Therapeutics's annual Other Current Payables increased from Jun. 2021 (A$1.00 Mil) to Jun. 2022 (A$1.67 Mil) and increased from Jun. 2022 (A$1.67 Mil) to Jun. 2023 (A$3.41 Mil).


Chimeric Therapeutics Other Current Payables Historical Data

The historical data trend for Chimeric Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Other Current Payables Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Other Current Payables
1.00 1.67 3.41

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Payables Get a 7-Day Free Trial - 1.67 - 3.41 -

Chimeric Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.


Chimeric Therapeutics Other Current Payables Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimeric Therapeutics (ASX:CHM) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines